REUN

Reunion Neuroscience Inc. Common Shares

REUN

Market cap $13.1M

Delisted

REUN was delisted on the 31st of July, 2023.

Back to rankings

About: Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Employees: 16

Healthcare Medical Care Facilities

Financial journalist opinion

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- Clinically Meaningful Reductions in MADRS Observed for RE104 30mg on the First Day Following Administration and Maintained Through Day 28 Follow-Up --

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology

-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated in Q3 2025 --

Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology

Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

-- Enrollment Completed on Schedule; Topline Results Expected Q3 2025 -- -- Company to Present Poster Reviewing RE104 Phase 1 Results at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May 28, 2025 --

Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference

-- AjD is a Mental Health Condition Triggered By a Stressful Life Event; Particularly Common in People with Serious Medical Illness -- -- AjD Represents an Area of Significant Unmet Need; No FDA-Approved Therapies Currently Available --

Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference

Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event

Reunion to Participate in the ‘New Treatment Options Panel' Discussion at the 2025 Maternal Mental Health FORUM on March 18 at 2:30 p.m. ET

Reunion Neuroscience Announces Participation in Premiere Maternal Mental Health Event

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025

Reunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 Milestones

Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, presented a poster detailing RE104 Phase 1 data at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona.

Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression

Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion's Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who will continue to remain involved with Reunion as a strategic advisor.

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression

Reunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention Month

See News Rankings

Charts implemented using Lightweight Charts™